Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
NCT ID: NCT07297914
Last Updated: 2025-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2/PHASE3
1000 participants
INTERVENTIONAL
2026-01-15
2032-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In response to these challenges, the FORUM consortium has made substantial progress in improving outcomes for children with ALL undergoing HSCT. The consortium focuses on reducing life-threatening and lifelong complications, ultimately aiming to enhance quality of life for these high-risk patients. Building on the robust evidence generated by FORUM1, the FORUM2 study has been designed to further optimize the role of HSCT in ALL across all age groups and donor settings within a harmonized and internationally coordinated framework.
The FORUM2 study introduces a master protocol structure that encompasses multiple hypothesis-driven substudies, each addressing a specific determinant of HSCT outcomes. This design enables simultaneous or sequential evaluation of novel strategies while ensuring uniform governance, endpoint definitions, and data-quality standards. The overarching objective is to refine the role of HSCT in ALL by reducing treatment-related toxicity while preserving the essential graft-versus-leukemia effect.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Optimization of conditioning regimens
* Advancements in GvHD prevention and treatment
* Integration of novel immunotherapies
* Improvement of long-term survivorship
* Harmonization of supportive care and post-transplant monitoring
* Expansion of donor availability The FORUM2 study comprises two randomized comparisons (R1 and R2 substudies), one stratified cohort (S1 substudy), and one pilot cohort (P1 substudy). The protocol is structured as a master protocol, with the R1 substudy serving as the central component because it represents the continuation of the FORUM1 study (which compared TBI-based and chemotherapy-based conditioning) and is expected to enroll the majority of patients.
Patients ineligible for the R1 substudy-due to age (\<2 years), donor type, physician discretion, or personal preference-will still be included in the master protocol and monitored accordingly. Patients transplanted from a mismatched family donor will be stratified within the S1 substudy. Additionally, patients younger than 2 years of age with B-ALL are eligible for the P1 pilot substudy, which will investigate the use of post-HSCT blinatumomab to reduce relapse incidence in this high-risk population.
Primary and secondary endpoints, general assessment timelines, and supportive care guidelines will remain consistent for both R1 substudy participants and patients included in the broader master protocol. Additional assessments, endpoints, and interventions specific to other study groups are outlined in their respective protocol sections (or appendices) and will be conducted exclusively for patients enrolled in those specific cohorts.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
* Two randomized comparison groups (R1 SUBSTUDY and R2 SUBSTUDY),
* One stratified cohort (S1 SUBSTUDY),
* One pilot cohort (P1 SUBSTUDY).
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
R1 substudy
A phase III, randomized, multi-center study comparing TBI 8 Gy versus TBI 12 Gy in children and young adults with ALL for conditioning of allogeneic HSCT
Total Body Irradiation 8 Gy
Total Body Irradiation 8 Gy administered in combination with VP16 as part of the conditioning regimen
Total Body Irradiation 12 Gy
Total Body Irradiation 12 Gy administered in combination with VP16 as part of the conditioning regimen
R2 substudy
A phase III, randomized, open-label multi-center study comparing ruxolitinib plus corticosteroids versus corticosteroids alone in children with ALL and treatment-naïve grade II-IV aGvHD following allogeneic HSCT
Ruxolitinib
Ruxolitinib plus corticosteroids in treatment-naïve acute graft-versus-host disease
Corticosteroids
Corticosteroids alone in treatment-naïve acute graft-versus-host disease
S1 substudy
A prospective stratified cohort study comparing between in vivo PT-Cy and ex vivo αβ T-cell depletion in mismatched donor transplantation for pediatric and young adult ALL.
Cyclophosphamide
In vivo T-cells depletion/modulation with post-transplant cyclophosphamide
αβ T-cells depletion
Ex vivo graft manipulation based on selective depletion of T-cell receptor αβ (TCR αβ+)/CD19+ lymphocytes from the graft (αβ T-cells depletion)
P1 substudy
A phase II, open-label, multi-center study of blinatumomab following allogeneic HSCT for B-lineage ALL in children younger than 2 years not receiving TBI as part of the conditioning regimen
Blinatumomab
Up to four cycles of blinatumomab as post-HSCT maintenance therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Total Body Irradiation 8 Gy
Total Body Irradiation 8 Gy administered in combination with VP16 as part of the conditioning regimen
Ruxolitinib
Ruxolitinib plus corticosteroids in treatment-naïve acute graft-versus-host disease
Blinatumomab
Up to four cycles of blinatumomab as post-HSCT maintenance therapy
Cyclophosphamide
In vivo T-cells depletion/modulation with post-transplant cyclophosphamide
Total Body Irradiation 12 Gy
Total Body Irradiation 12 Gy administered in combination with VP16 as part of the conditioning regimen
Corticosteroids
Corticosteroids alone in treatment-naïve acute graft-versus-host disease
αβ T-cells depletion
Ex vivo graft manipulation based on selective depletion of T-cell receptor αβ (TCR αβ+)/CD19+ lymphocytes from the graft (αβ T-cells depletion)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥3 months to ≤25 years at the time of HSCT.
* Patients must be in complete remission (with \<5% blasts and absence of leukemia cells in extramedullary sites) prior to undergoing HSCT.
* Selected donor must be either a matched donor (matched donor category includes 9/10 identical siblings and 10/10 or 9/10 HLA-matched unrelated donors) or a mismatched family donor (≤8/10 HLA match). Either bone marrow or peripheral blood stem cell grafts are permitted. Cord blood is permitted, as well, provided that the unit is at least 6/8 HLA matched and with a cryopreserved cellularity of at least 3x107 nucleated cells/Kg recipient body weight.
* Female patients of childbearing potential must have a negative pregnancy test at screening, and all patients must agree to adhere to effective contraception during the study period.
* Written study informed consent and/or assent from the patient and/or the parent, or guardian
Exclusion Criteria
* Patients not in complete morphological remission at the time of enrollment.
* Patients with an initial diagnosis of Non-Hodgkin Lymphoma (NHL).
* Patients with ALL as a secondary malignancy.
* Patients with a history of previous autologous or allogeneic HSCT (prior allogeneic transplantation is permitted for subjects receiving post-transplant interventions, such as those enrolled in the R2 and P1 substudies, provided that this is their first allogeneic HSCT).
* Female patients who are pregnant or breast feeding.
* Fertile male or female patients of childbearing potential who do not agree to abstinence or, if sexually active, do not agree to the use of contraception.
* Active clinically uncontrolled bacterial, fungal, parasitic, or viral infection. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no physical or radiographic signs of infection progression are present.
* Active HBV or HCV infection that requires treatment, or at risk for HBV reactivation (e.g. positive HBsAg). Subjects with negative HbsAg and positive total HB core antibody may be included if HBV DNA is undetectable at the time of screening. Subjects who are positive for HCV antibody are eligible only if polymerase chain reaction test is negative for HCV RNA. Subjects whose immune status is unknown or uncertain must have results confirming immune status before enrollment. Prior serology results are acceptable for determining eligibility.
* Known human immunodeficiency virus infection (HIV).
* Significant respiratory disease including patients who are on mechanical ventilation or who have resting O2 saturation \<90% by pulse-oximetry on room-air.
* Presence of severely impaired renal function (confirmed within 72 hours prior to study treatment start) defined by:
* Glomerular Filtration Rate (GFR) \< 30 mL/min/1.73 m2 using estimated creatinine clearance calculated by updated bedside Schwartz equation or Cockcroft Gault equation OR
* Renal dialysis requirement
* Clinically significant or uncontrolled cardiac disease including any of the following:
* Uncontrolled hypertension
* New York Heart Association Class III or IV congestive heart failure
* Clinically significant cardiac arrhythmias
* Severe hepatic insufficiency, defined by any of the following:
* Child-Pugh Class C liver disease
* AST (aspartate aminotransferase) or ALT (alanine aminotransferase) levels \> 5 times the upper limit of normal (ULN), unless attributable to GvHD
* Total bilirubin \> 3.0 mg/dL, unless attributable to GvHD
* INR (International Normalized Ratio) ≥ 1.7
* Clinical evidence of hepatic encephalopathy or ascites
* Presence of severe concomitant constitutional disease that precludes treatment as per protocol, based on the investigator's judgment. Examples include but are not limited to: Down syndrome with severe comorbidities, significant cardiac malformations, and metabolic disorders affecting treatment feasibility.
* Underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere participation in the study, pose a significant risk to the patient or interfere with interpretation of study data.
* Karnofsky or Lansky performance score \<50%, indicating significant functional impairment.
* Patients who are unwilling or unable to comply with study procedures, including follow-up requirements and treatment schedules.
3 Months
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bambino Gesù Hospital and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Franco Locatelli, Professor
Role: PRINCIPAL_INVESTIGATOR
IRCSS Ospedale Pediatrico Bambino Gesù
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St'Anna Children Hospital
Vienna, , Austria
University Hospital Motol
Prague, , Czechia
Rigshopsitalet, University Hospital
Copenhagen, , Denmark
HUS-Yhtymae (HUS Helsinki University Hospital)
Helsinki, , Finland
Robert- Debré Academic Hospital
Paris, , France
Goethe-Universität
Frankfurt, , Germany
IRCCS Ospedale Pediatrico Bambino Gesù
Roma, RM, Italy
University Hospital
Oslo, , Norway
University of Medical Sciences
Poznan, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Oostenbrink LVE, Von Asmuth EGJ, Jol-van der Zijde CM, Jansen-Hoogendijk AM, Vervat C, Bredius RGM, Van Tol MJD, Schilham MW, Sedlacek P, Ifversen M, Balduzzi A, Bader P, Peters C, Moes DJAR, Lankester AC. Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study. Haematologica. 2024 Sep 1;109(9):2854-2863. doi: 10.3324/haematol.2023.284632.
Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, Vettenranta K, Svec P, Aleinikova O, Stein J, Gungor T, Toporski J, Truong TH, Diaz-de-Heredia C, Bierings M, Ariffin H, Essa M, Burkhardt B, Schultz K, Meisel R, Lankester A, Ansari M, Schrappe M; IBFM Study Group;; von Stackelberg A; IntReALL Study Group; Balduzzi A; I-BFM SCT Study Group; Corbacioglu S; EBMT Paediatric Diseases Working Party; Bader P. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021 Feb 1;39(4):295-307. doi: 10.1200/JCO.20.02529. Epub 2020 Dec 17.
Bader P, Potschger U, Dalle JH, Moser LM, Balduzzi A, Ansari M, Buechner J, Gungor T, Ifversen M, Krivan G, Pichler H, Renard M, Staciuk R, Sedlacek P, Stein J, Heusel JR, Truong T, Wachowiak J, Yesilipek A, Locatelli F, Peters C. Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study. Blood Adv. 2024 Jan 23;8(2):416-428. doi: 10.1182/bloodadvances.2023010591.
Kalwak K, Moser LM, Potschger U, Bader P, Kleinschmidt K, Meisel R, Dalle JH, Yesilipek A, Balduzzi A, Krivan G, Goussetis E, Staciuk R, Sedlacek P, Pichler H, Svec P, Gabriel M, Gungor T, Bilic E, Buechner J, Renard M, Vettenranta K, Ifversen M, Diaz-de-Heredia C, Stein J, Toporski J, Bierings M, Peters C, Ansari M, Locatelli F. Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM. Blood Adv. 2025 Feb 25;9(4):741-751. doi: 10.1182/bloodadvances.2024014548.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FORUM2
Identifier Type: -
Identifier Source: org_study_id
2025-522052-13-00
Identifier Type: CTIS
Identifier Source: secondary_id